| # | Drug | Count |
|---|---|---|
| 0 | ECULIZUMAB | 176 |
| 1 | RUXOLITINIB | 84 |
| 2 | RITUXIMAB | 55 |
| 3 | CYCLOPHOSPHAMIDE | 42 |
| 4 | CYCLOPHOSPHAMIDE FOR INJECTION | 42 |
| 5 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 42 |
| 6 | CYTARABINE | 39 |
| 7 | PEMBROLIZUMAB | 36 |
| 8 | DEXAMETHASONE | 34 |
| 9 | DEXAMETHASONE 1.5 MG | 34 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | CAPLACIZUMAB | 9 | 0.0050 |
| 1 | PEGCETACOPLAN | 7 | 0.0037 |
| 2 | ECULIZUMAB | 176 | 0.0032 |
| 3 | BRENTUXIMAB VEDOTIN | 18 | 0.0017 |
| 4 | VINORELBINE | 12 | 0.0017 |
| 5 | BENDAMUSTINE HCL | 25 | 0.0016 |
| 6 | AMPHOTERICIN B | 16 | 0.0012 |
| 7 | RUXOLITINIB | 84 | 0.0011 |
| 8 | CYTARABINE | 39 | 0.0006 |
| 9 | DASPONE | 6 | 0.0006 |
| # | Drug class | Count |
|---|---|---|
| 0 | Complement Inhibitor [EPC] | 183 |
| 1 | Kinase Inhibitor [EPC] | 104 |
| 2 | Corticosteroid [EPC] | 89 |
| 3 | Janus Kinase Inhibitor [EPC] | 87 |
| 4 | Nucleoside Metabolic Inhibitor [EPC] | 58 |
| 5 | CD20-directed Cytolytic Antibody [EPC] | 56 |
| 6 | Alkylating Drug [EPC] | 47 |
| 7 | Nonsteroidal Anti-inflammatory Drug [EPC] | 44 |
| 8 | Platinum-based Drug [EPC] | 43 |
| 9 | HMG-CoA Reductase Inhibitor [EPC] | 27 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Complement Inhibitor [EPC] | 183 | 0.0033 |
| 1 | Pyruvate Kinase Activator [EPC] | 4 | 0.0030 |
| 2 | Adrenal Steroid Synthesis Inhibitor [EPC] | 3 | 0.0030 |
| 3 | CD123 Interaction [EPC] | 1 | 0.0019 |
| 4 | CD30-directed Immunoconjugate [EPC] | 18 | 0.0017 |
| 5 | CD3-directed Antibody [EPC] | 1 | 0.0014 |
| 6 | Lipid-based Polyene Antifungal [EPC] | 16 | 0.0012 |
| 7 | Selective T Cell Costimulation Blocker [EPC] | 3 | 0.0006 |
| 8 | Sulfone [EPC] | 6 | 0.0006 |
| 9 | Janus Kinase Inhibitor [EPC] | 87 | 0.0005 |